Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience.
We report the clinical outcome of a 46-year-old diabetic patient with cystoid macular edema treated with Sandostatin long-acting release (LAR). Because cystoid changes in both eyes were refractive to conventional treatment (i.e., vitrectomy and periocular steroids), the patient was treated with Sandostatin LAR 20 mg every four weeks. One year later the patient maintained corrected visual acuity of 20/40 in the right eye and 20/100 in the left eye, the cystoid changes had disappeared in the right eye and had greatly decreased in the left eye. In addition, the intraocular pressure had declined and no other complications were found. Thus, Sandostatin LAR may be considered for the treatment of diabetic patients with cystoid macular edema.
Hernaez-Ortega
Maria Concepcion
MC
European Innovative Biomedicine Institute, C/Jardines 2, 1-G, 39700 Cantabria, Spain. eibi@eurodiab.com
Soto-Pedre
Enrique
E
Martin
Juan Jose Beitia
JJ
D003692:Delayed-Action Preparations; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D008269:Macular Edema / Q000175:diagnosis* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D015282:Octreotide